| Symbol | MRZM |
|---|---|
| Name | MARIZYME, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 33458 United States FL 555 Heritage Drive Suite 205 |
| Telephone | (561)935-9955 |
| Fax | — |
| — | |
| Website | http://www.marizyme.com |
| Incorporation | US |
| Incorporated On | 2007 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | WithumSmith + Brown PC; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001413754 |
| Description | Marizyme, Inc. is a medical technology company changing the landscape of cardiac care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery. Marizymes first in-class product, DuraGraft™, was granted a de novo clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™, with its CE Mark, continues to drive sales growth for Marizyme internationally in Europe and Asia, and will now target the U.S. market to drive further utilization and sales. Additional info from OTC: |
(42% Neutral) MARIZYME, INC. (MRZM) Reports 407% Loss Increase for 2024-09-30
Read moreOTCQB symbol attribute type Security_Name was changed. Previous value: -. New value: MARIZYME INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: MARIZYME INC.
Read more(71% Positive) MARIZYME, INC. (MRZM) Reports 59% Loss Reduction for 2024-03-31
Read more